Short-term outcomes of endoscopic sleeve gastroplasty in 1000 consecutive patients.
Adolescent
Adult
Ambulatory Surgical Procedures
Diabetes Mellitus, Type 2
/ complications
Dyslipidemias
/ complications
Female
Gastroplasty
/ methods
Gastroscopy
/ methods
Humans
Hypertension
/ complications
Male
Middle Aged
Obesity, Morbid
/ complications
Pain, Postoperative
/ epidemiology
Patient Readmission
/ statistics & numerical data
Postoperative Hemorrhage
/ epidemiology
Postoperative Nausea and Vomiting
/ epidemiology
Prospective Studies
Weight Loss
Young Adult
Journal
Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
28
08
2018
accepted:
09
12
2018
pubmed:
24
12
2018
medline:
10
1
2020
entrez:
23
12
2018
Statut:
ppublish
Résumé
Questions related to the safety and long-term efficacy of endoscopic sleeve gastroplasty (ESG) are not yet answered. Here we report weight loss, morbidity, revisions, and comorbidity resolution during the first 18 months after primary ESG. This is a consecutive case series from a prospective observational study executed in a specialized center with a standardized pathway for multimodal management of obesity. The 1000 patients in this study had a baseline body mass index of 33.3 ± 4.5 kg/m ESG appears to be well tolerated, safe, and effective. Significant weight loss occurs during the first 18 months without mortality or significant morbidity. Some patients require revision or reversal during the first year.
Sections du résumé
BACKGROUND AND AIMS
Questions related to the safety and long-term efficacy of endoscopic sleeve gastroplasty (ESG) are not yet answered. Here we report weight loss, morbidity, revisions, and comorbidity resolution during the first 18 months after primary ESG.
METHODS
This is a consecutive case series from a prospective observational study executed in a specialized center with a standardized pathway for multimodal management of obesity.
RESULTS
The 1000 patients in this study had a baseline body mass index of 33.3 ± 4.5 kg/m
CONCLUSIONS
ESG appears to be well tolerated, safe, and effective. Significant weight loss occurs during the first 18 months without mortality or significant morbidity. Some patients require revision or reversal during the first year.
Identifiants
pubmed: 30578757
pii: S0016-5107(18)33363-7
doi: 10.1016/j.gie.2018.12.012
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1132-1138Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.